With 2.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.63 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $21.7 whereas the lowest price it dropped to was $15.51. The 52-week range on TNXP shows that it touched its highest point at $1193.28 and its lowest point at $6.76 during that stretch. It currently has a 1-year price target of $400.00. Beta for the stock currently stands at 1.72.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TNXP was up-trending over the past week, with a rise of 50.62%, but this was up by 71.80% over a month. Three-month performance dropped to -10.31% while six-month performance rose 30.93%. The stock lost -98.07% in the past year, while it has lost -37.75% so far this year.
Float and Shares Shorts:
On 2025-02-28, short shares totaled 0.55 million, which was 986.0 higher than short shares on 1738281600. In addition to Dr. Seth Lederman M.D. as the firm’s Co-Founder, President, CEO & Chairman, Mr. Bradley Saenger CPA serves as its CFO & Treasurer.
Institutional Ownership:
Through their ownership of 0.03322 of TNXP’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, TNXP reported revenue of $2822000.0 and operating income of -$13886000.0. The EBITDA in the recently reported quarter was -$13376000.0 and diluted EPS was -$0.23.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TNXP since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TNXP analysts setting a high price target of 1100.0 and a low target of 50.0, the average target price over the next 12 months is 516.6667. Based on these targets, TNXP could surge 5258.01% to reach the target high and rise by 143.55% to reach the target low. Reaching the average price target will result in a growth of 2416.64% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$7.47007 being high and -$219.52993 being low. For TNXP, this leads to a yearly average estimate of -$113.5.
